GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 125 participants.

Also called NCT06003153

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 125 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06003153
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06003153. Allocation not applicable; no masking; primary purpose treatment. Start 2024-03-12 (actual); primary completion 2027-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
Acronym
GLUCOSE-MGH
Condition
Genetic Predisposition
Condition
Metabolic Diseases
Intervention (Drug)
oral semaglutide
Intervention (Other)
Mixed Meal Tolerance Test (MMTT)
Lead sponsor
Massachusetts General Hospital (class: other)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct06003153
Content hash
43167cabbcccb76fea3f2f9494a86ee2a53e5333f30b039f8547d3bbedf884ad